Latest Conference Articles

Explore top dermatology conferences and meetings in June 2026 and let us know which ones you'll be attending!

Albert Chiou, MD, MBA, reviews updates presented at SID 2026 on phase 1 data showing soquelitinib activity in prior systemic therapy failures, with a well-balanced adverse event profile vs placebo.

Explore evidence-backed nutricosmetics and hormone-aware nutrition for women’s skin and hair—plus what to know about collagen and dosing.

Prospective data presented at ASLMS by Isabella Camacho-Hubbard, MD, shows Stellar M22 XPL Glide boosts photodamage results, speeds treatments, avoids striping, and maintains safety.

Albert Chiou, MD, MBA, discusses results from the phase 1 trial of soquelitinib for moderate to severe AD presented at SID 2026.

The growing success of IL-17–targeted therapies suggests that remission may become a realistic future goal for many patients living with hidradenitis suppurativa.

At EULAR 2026, investigators presented head-to-head data demonstrating significantly higher joint response rates with bimekizumab compared with risankizumab in PsA.

Biologics and oral JAK inhibitors are now strongly recommended for moderate to severe pediatric AD, signaling a shift toward earlier systemic treatment escalation.

Dermatology Times' editor in chief highlights essential late-breaker data from AAD 2026, including upadacitinib, rezpegaldesleukin, icotrokinra, zasocitinib, envudeucitinib, sonelokimab, and more.

David Oberlin, MD, said the true value of AAD begins when clinicians return to practice and apply new knowledge to patient care.

Dermatology Times' editor in chief highlights essential late-breakers from AAD 2026, including rademikibart, KT-621, nemolizumab, and delgocitinib.

A 24-week trial shows ruxolitinib cream sustains control and itch relief in moderate atopic dermatitis when steroids fail, with a positive safety profile.

Explore top dermatology conferences and meetings in May 2026 and let us know which ones you'll be attending!

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress, including laughter yoga, relationships, and mindset shifts

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress — from family time and fitness to emotional intelligence training and even Botox.

Gain exclusive insights from AAD on rapid-onset topicals, durable biologic control, and a growing emphasis on stringent, patient-centered targets shaping atopic dermatitis care.

At the 2026 Winter Clinical Miami meeting, dermatology leaders emphasized that thriving careers require skills beyond clinical expertise.

New 140-week data show that upadacitinib keeps itch, sleep, and quality-of-life gains steady in patients with moderate to severe atopic dermatitis (AD).

Post hoc trial data presented at AAD 2026 show near-clear atopic dermatitis and minimal itch drive bigger gains in quality of life, sleep, mental health, and satisfaction.

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

A retrospective claims analysis found that nearly half of patients newly diagnosed with vitiligo by a dermatologist did not initiate therapy, and those who did showed low persistence across treatment categories.

Work productivity loss fell from 44.3% at baseline to 19.0% at week 52 in the total study population, representing a clinically meaningful reduction in occupational impairment over the full treatment period.

Late-breaking data presented at AAD 2026 showed that upadacitinib 15 mg produced statistically significant, progressively improving repigmentation in adults and adolescents with non-segmental vitiligo through 48 weeks.

David Oberlin, MD, shares tips for integrating AAD insights and lessons into the clinic to improve patient care.

At AAD 2026, Lauren Madigan, MD, presented long-term PIONEER trial extension data and urged clinicians to sharpen their recognition of 2 clonally driven inflammatory diseases: indolent systemic mastocytosis and VEXAS syndrome.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss phase 3 data presented at AAD showing patients moving from very severe disease at baseline to absent or mild disease by week 40.